Vaccines and Biodefense

William Schaffner, MD, the immediate past president of the National Foundation for Infectious Diseases, explains why it is important for all adults to become fully immunized according to recommended schedules.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

In recognition of National Infant Immunization Week, Dr. Yabo Beysolow, Medical Officer at the CDC, talks about the benefits of immunization for children under the age of two.

Learn about the role biotechnology plays in the on-going fight against HIV/AIDS.

Since the development of the first vaccine by Edward Jenner in 1796, we have seen tremendous progress in our ability to prevent deadly childhood infections.

Paul A. Offit, M.D. is Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia. Dr. Offit received this year's BIO Humanitarian Award at the 2011 BIO International Convention in Washington, DC.  Dr. Dr. Dr.

Phyllis Arthur interviews Colonel Randall Larsen, CEO of the WMD Center, on the threat of a pandemic as portrayed in the movie Contagion which opens in theatres nationwide today.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Paul A. Offit, MD was named the 2011 Biotech Humanitarian Award winner.

Dr. Tettelin discusses his research in reverse vaccinology and as a pioneer of the pan-genome concept.

A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant.

As we celebrate World Health Day today, it is an opportunity to remember that vaccines represent one of the most important global health investments.

As Japan works to stabilize the crippled nuclear power plant in Fukushima, people are stocking up on potassium iodide tablets – one of the only drugs available to block the body's absorption of some radioactive materials.

Bringing biotechs into global health R&D.

Letters, Testimony & Comments

July 1 2015
On June 15, 2015, the Department of Defense's (DoD's) Joint Project Manager-Medical Countermeasure Systems (JPM-MCS) held a co-located Industry Day in conjunction with the BIO Convention in Philadelphia, Pennsylvania. The MCS Industry Day focused on industry feedback related to the DoD's proposed use of an Other Transaction Authority (OTA) contracting mechanism. 
March 7 2014
On March 7, 2014, BIO submitted comments to the U.S. Office of Personnel Management (OPM) regarding OPM’s February 4, 2014 Multi-State Plan (MSP) Program Call Letter. BIO’s comments address the critical nature of the Affordable Care Act’s immunization coverage standard.
February 25 2014
BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization Action Coalition (IAC), Merck, and the National Association of County and City Health Officials (NACCHO) to submit comments to the Centers for Medicare and Medicaid Services (CMS) regarding the February 4, 2014 Draft Letter to Issuers in the Federally-facilitated Marketplaces. 
December 19 2013
BIO submitted comments on the Centers for Medicare and Medicaid Services' (CMS’s) Federally Qualified Health Center (FQHC) Prospective Payment System (PPS) proposed rule, specifically as it relates to vaccine coverage for Medicare beneficiaries and reimbursement for vaccines under Medicare Part B.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.

Press Releases

April 29 2015
Washington, D.C. (April 29, 2015) – The Biotechnology Industry Organization (BIO) today releases the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI), Rep. Diana DeGette (D-CO), Rep. Frank Pallone, Jr. (D-NJ), Rep. Joe Pitts (R-PA), and Rep. Gene Green (D-TX). 
February 6 2015
Bill would encourage vaccine research and benefit public health Washington, D.C. (February 6, 2015) – The Biotechnology Industry Organization (BIO) applauds the introduction of the Vaccine Access, Certainty, and Innovation Act of 2015. Sponsored by Representatives Renee Ellmers (R-NC) and G.K. Butterfield (D-NC), the Act is expected to be an important part of the Energy & Commerce Committee’s 21st Century Cures Initiative and would modernize the discovery, development, and delivery of vaccines. 
December 9 2014
Washington, D.C. (December 9, 2014) – The Biotechnology Industry Organization (BIO) applauds today’s declaration by Health and Human Services Secretary Sylvia M. Burwell under the Public Readiness and Emergency Preparedness (PREP) Act which will help advance the development and availability of experimental Ebola vaccines. The declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of three experimental Ebola vaccines.
December 4 2014
Washington, D.C. (December 4, 2014) – Today marks the inaugural meeting of the Blue Ribbon Study Panel on Biodefense, a bipartisan panel co-chaired by former Senator Joe Lieberman and former Governor and Homeland Security Secretary Tom Ridge. Panelists former Senator Tom Daschle, former Secretary of Health and Human Services Donna Shalala, former US Homeland Security Advisor Kenneth Wainstein, and Biotechnology Industry Organization (BIO) President and CEO and former Representative Jim Greenwood. The study will be directed by Dr. Robert Kadlec, former special assistant to the President for homeland security and senior director for biological defense policy in the White House Homeland Security Council.
June 20 2013
BIO applauds Sens. Max Baucus (D-MT) and Orrin Hatch (R-UT) and Reps. Jim Gerlach (R-PA) and Richard Neal (D-MA) on the passage of H.R. 475 to update the existing excise tax to cover the newest seasonal influenza vaccines.